Logo image of ANGO

ANGIODYNAMICS INC (ANGO) Stock Fundamental Analysis

NASDAQ:ANGO - Nasdaq - US03475V1017 - Common Stock - Currency: USD

9.41  -0.16 (-1.67%)

After market: 9.41 0 (0%)

Fundamental Rating

2

ANGO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. ANGO may be in some trouble as it scores bad on both profitability and health. ANGO is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ANGO had negative earnings in the past year.
ANGO had a negative operating cash flow in the past year.
ANGO had negative earnings in each of the past 5 years.
In multiple years ANGO reported negative operating cash flow during the last 5 years.
ANGO Yearly Net Income VS EBIT VS OCF VS FCFANGO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -14.50%, ANGO is in line with its industry, outperforming 56.08% of the companies in the same industry.
With a decent Return On Equity value of -22.27%, ANGO is doing good in the industry, outperforming 60.85% of the companies in the same industry.
Industry RankSector Rank
ROA -14.5%
ROE -22.27%
ROIC N/A
ROA(3y)-24.22%
ROA(5y)-21.27%
ROE(3y)-36.59%
ROE(5y)-30.72%
ROIC(3y)N/A
ROIC(5y)N/A
ANGO Yearly ROA, ROE, ROICANGO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

With a Gross Margin value of 54.36%, ANGO perfoms like the industry average, outperforming 48.15% of the companies in the same industry.
ANGO's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for ANGO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54.36%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.88%
GM growth 5Y-2.46%
ANGO Yearly Profit, Operating, Gross MarginsANGO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

More info and screens

3

2. Health

2.1 Basic Checks

ANGO does not have a ROIC to compare to the WACC, probably because it is not profitable.
ANGO has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ANGO has more shares outstanding
There is no outstanding debt for ANGO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ANGO Yearly Shares OutstandingANGO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
ANGO Yearly Total Debt VS Total AssetsANGO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

ANGO has an Altman-Z score of 1.35. This is a bad value and indicates that ANGO is not financially healthy and even has some risk of bankruptcy.
ANGO has a Altman-Z score (1.35) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.03 indicates that ANGO is not too dependend on debt financing.
ANGO's Debt to Equity ratio of 0.03 is fine compared to the rest of the industry. ANGO outperforms 64.02% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z 1.35
ROIC/WACCN/A
WACC8.9%
ANGO Yearly LT Debt VS Equity VS FCFANGO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

ANGO has a Current Ratio of 2.21. This indicates that ANGO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.21, ANGO is doing worse than 60.32% of the companies in the same industry.
A Quick Ratio of 1.40 indicates that ANGO should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.40, ANGO is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.21
Quick Ratio 1.4
ANGO Yearly Current Assets VS Current LiabilitesANGO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 41.94% over the past year.
Looking at the last year, ANGO shows a very negative growth in Revenue. The Revenue has decreased by -12.56% in the last year.
Measured over the past years, ANGO shows a small growth in Revenue. The Revenue has been growing by 2.35% on average per year.
EPS 1Y (TTM)41.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%118.75%
Revenue 1Y (TTM)-12.56%
Revenue growth 3Y1.46%
Revenue growth 5Y2.35%
Sales Q2Q%-4.23%

3.2 Future

The Earnings Per Share is expected to grow by 27.82% on average over the next years. This is a very strong growth
Based on estimates for the next years, ANGO will show a small growth in Revenue. The Revenue will grow by 5.85% on average per year.
EPS Next Y24.15%
EPS Next 2Y18.62%
EPS Next 3Y30.75%
EPS Next 5Y27.82%
Revenue Next Year-2.08%
Revenue Next 2Y2.05%
Revenue Next 3Y3.79%
Revenue Next 5Y5.85%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ANGO Yearly Revenue VS EstimatesANGO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 100M 200M 300M
ANGO Yearly EPS VS EstimatesANGO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 0.2 -0.2 0.4 -0.4 0.6 0.8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ANGO. In the last year negative earnings were reported.
Also next year ANGO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANGO Price Earnings VS Forward Price EarningsANGO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

ANGO's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. ANGO is cheaper than 62.43% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 7146.48
ANGO Per share dataANGO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

ANGO's earnings are expected to grow with 30.75% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.62%
EPS Next 3Y30.75%

More info and screens

0

5. Dividend

5.1 Amount

ANGO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANGIODYNAMICS INC

NASDAQ:ANGO (5/22/2025, 8:00:00 PM)

After market: 9.41 0 (0%)

9.41

-0.16 (-1.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-02 2025-04-02/bmo
Earnings (Next)07-14 2025-07-14/amc
Inst Owners83.14%
Inst Owner Change12.59%
Ins Owners5.35%
Ins Owner Change1.81%
Market Cap382.14M
Analysts84.44
Price Target15.98 (69.82%)
Short Float %3.9%
Short Ratio2.91
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)93.49%
Min EPS beat(2)64.35%
Max EPS beat(2)122.62%
EPS beat(4)4
Avg EPS beat(4)69.54%
Min EPS beat(4)26.47%
Max EPS beat(4)122.62%
EPS beat(8)6
Avg EPS beat(8)36.68%
EPS beat(12)8
Avg EPS beat(12)5.72%
EPS beat(16)11
Avg EPS beat(16)5.43%
Revenue beat(2)2
Avg Revenue beat(2)0.55%
Min Revenue beat(2)0.41%
Max Revenue beat(2)0.68%
Revenue beat(4)2
Avg Revenue beat(4)-0.82%
Min Revenue beat(4)-2.6%
Max Revenue beat(4)0.68%
Revenue beat(8)2
Avg Revenue beat(8)-1.72%
Revenue beat(12)3
Avg Revenue beat(12)-1.75%
Revenue beat(16)5
Avg Revenue beat(16)-1.13%
PT rev (1m)2.17%
PT rev (3m)2.17%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-33.33%
EPS NY rev (1m)0%
EPS NY rev (3m)21.62%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.25%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.61%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.35
P/FCF N/A
P/OCF N/A
P/B 2.06
P/tB 3.32
EV/EBITDA 7146.48
EPS(TTM)-0.18
EYN/A
EPS(NY)-0.23
Fwd EYN/A
FCF(TTM)-0.69
FCFYN/A
OCF(TTM)-0.59
OCFYN/A
SpS6.98
BVpS4.58
TBVpS2.83
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.5%
ROE -22.27%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 54.36%
FCFM N/A
ROA(3y)-24.22%
ROA(5y)-21.27%
ROE(3y)-36.59%
ROE(5y)-30.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.88%
GM growth 5Y-2.46%
F-Score4
Asset Turnover0.99
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA 120.41
Cap/Depr 15.88%
Cap/Sales 1.5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.21
Quick Ratio 1.4
Altman-Z 1.35
F-Score4
WACC8.9%
ROIC/WACCN/A
Cap/Depr(3y)16.52%
Cap/Depr(5y)20.29%
Cap/Sales(3y)1.51%
Cap/Sales(5y)1.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%118.75%
EPS Next Y24.15%
EPS Next 2Y18.62%
EPS Next 3Y30.75%
EPS Next 5Y27.82%
Revenue 1Y (TTM)-12.56%
Revenue growth 3Y1.46%
Revenue growth 5Y2.35%
Sales Q2Q%-4.23%
Revenue Next Year-2.08%
Revenue Next 2Y2.05%
Revenue Next 3Y3.79%
Revenue Next 5Y5.85%
EBIT growth 1Y13.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year107.33%
EBIT Next 3Y46.49%
EBIT Next 5Y34.24%
FCF growth 1Y-141.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-227.02%
OCF growth 3YN/A
OCF growth 5YN/A